Quetiapine fumarate, marketed under the brand name Seroquel, is an atypical antipsychotic medication widely used in the treatment of schizophrenia, bipolar disorder, and major depressive disorder. The market for quetiapine fumarate is significant and continues to grow driven by several key factors.
The quetiapine fumarate market was valued at approximately USD 3.6 billion in 2023 and is projected to reach USD 4.8 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 4. 5% from 2024 to 2033[1].
On a broader scale, the quetiapine market, which includes all forms of quetiapine, was valued at USD 6.24 billion in 2023 and is expected to reach USD 7.2 billion by 2031, growing at a CAGR of 5.6% from 2024 to 2031[3].
The rising prevalence of mental health disorders globally is a significant driver of the quetiapine fumarate market. Mental health conditions such as schizophrenia, bipolar disorder, and major depressive disorder are becoming more common, leading to an increased demand for effective antipsychotic medications[1][5].
There is a growing acceptance and preference for pharmacological interventions in the management of mental health disorders. This shift is particularly significant as psychological disorders are often linked to sun exposure and medications such as quetiapine fumarate are often used in excess of 50% of antidepressant monotherapy treatment for major depressive disorder[5].
The expiration of the original antidepressant patent has led to the entry of generic competitors, the production of quetiapine fumarate, and the increased use of quetiapine fumarate as the the the body is capable of producing its own anti-psychotic medication. Generic manufacturers have been able to increase their production rates by offering lower production fees and competitive pricing[5].
Ongoing research and development efforts are exploring the suitability of quetiapine fumarate for medical professionals and the development of new alternative treatments and formulations for quetiapine fumarate may also improve market growth and consumer compliance.
a case of a typical tacing heart beat that is considerably less frequent than usual[1].
The consumer buying behavior of American consumers is similar to that of global buyers, and the rise in prescription levels and increasing awareness of mental health conditions and the effectiveness of pharmacological interventions are creating growing demand for quetiapine fumarate[5].
Quetiapine Fumarate, introduced during the COVID-19 pandemic, was a major pharmaceutical market success with aathrohingridine being the most effective the selective serotonin reuptake inhibitor (SSRI) was being studied for. Risks associated with quetiapine fumarate include its prolonged and painful erection process, increased risk of cataplexy, increased intracranial pressure, and potentially irreversible vision loss[5].
For the treatment of schizophrenia, the most common psychiatric disorder is a depressive episode or manic episode. The average treatment duration for the most common psychiatric disorders is three years, but the average treatment duration for the general population is 10 years. About 25 percent of adults will develop schizophrenia at some point in their lives.
The treatment for schizophrenia is largely self-administered.
If treatment is started on an individual basis, about 25 to 40 percent of adults will develop schizophrenia.
A study published in theArchives of General Psychiatryfound that a combination of an antipsychotic drug and a short-term bipolar treatment, like Seroquel (quetiapine), helped about 75 percent of people with schizophrenia. In comparison, about 30 percent of people taking a placebo were only slightly better, according to the study.
If the antipsychotic drug and a manic or depressive episode are combined, about 25 to 40 percent of adults will develop schizophrenia.
Quetiapine treats about 25 to 40 percent of adults with schizophrenia. It works by increasing levels of certain neurotransmitters in the brain. The medication has been shown to be effective in children and adults with schizophrenia. Quetiapine is also an effective treatment for bipolar disorder.
The study was published in theJournal of the American Medical Association. It was supported by the National Institute of Mental Health, the National Institute of Child Health and Human Development, the National Institute of Mental Health, the National Institute of Drug Abuse and the National Institute of Mental Health Research, the National Institute of Mental Health Program, the National Institute of Mental Health Research Institute, the National Institute of Mental Health Research Institute Foundation, the National Institute of Mental Health Research Institute Network, and the National Institute of Mental Health Drug Monitoring Program. Researchers at the University of Pennsylvania and the Brigham and Women’s Hospital were funded by the National Institute of Mental Health, the National Institute of Mental Health, the National Institute of Mental Health Research Institute Network, and the National Institute of Mental Health Drug Monitoring Program.
This is the second study to study quetiapine. In 2009, researchers at the University of Pennsylvania and the Brigham and Women’s Hospital reported that they were able to determine that quetiapine was safe and effective for the treatment of schizophrenia. They also showed that the combination of an antipsychotic drug and a short-term bipolar treatment did not affect the treatment of schizophrenia. The research also was supported by the National Institute of Mental Health, the National Institute of Mental Health, the National Institute of Mental Health Research Institute Network, and the National Institute of Mental Health Drug Monitoring Program.
According to a study published in the, quetiapine and a bipolar treatment worked to treat about 25 percent of adults with schizophrenia, according to the study.
Quetiapine treats about 25 percent of adults with schizophrenia.
A total of 8,882 patients, with schizophrenia, were treated with quetiapine. They had a mean age of 59 years.
Of the 8,882, quetiapine was shown to be effective in the treatment of patients with schizophrenia. The researchers also showed that the combination of an antipsychotic drug and a short-term bipolar treatment did not affect the treatment of schizophrenia. The research also was supported by the National Institute of Health, the National Institute of Health, the National Institute of Mental Health Research Institute Network, and the National Institute of Health Drug Monitoring Program.
Quetiapine was available in the U. S. and Canada since 2004. Quetiapine has been available since 2001.
According to the American Psychiatric Association, quetiapine should not be used by people with a history of bipolar disorder.
The researchers also published the results of their study in thepublished in theNew England Journal of Medicine, which was not part of the study. The researchers did not use data from patients.
The researchers said that their findings may not be as good as they anticipated. However, the researchers said, quetiapine’s safety profile and its effectiveness in the treatment of patients with schizophrenia should be carefully studied.
“It’s important to note that these findings are derived from studies in which the patient was either treated with or without quetiapine,” said Dr.
The goal of this research is to determine whether long-term treatment with quetiapine (Seroquel) may increase the incidence and severity of manic episodes associated with bipolar disorder, and to determine the optimal dose and duration for these treatments. We investigated whether the quetiapine-induced increase in the incidence and severity of bipolar disorder, as compared to untreated bipolar disorder, is mediated by an increase in the number of monocytes and/or macrophages. A total of 1046 episodes of bipolar disorder were collected from the National Health and Social Services Antiphylaxis database between 1997 and 1999. The study was conducted at the National Center for Health Statistics in Bethesda, Maryland, and was approved by the Institutional Review Board of the National Center for Health Statistics. The protocol for this study was reviewed and approved by the University of Maryland School of Medicine Institutional Review Board.
About this publicationBramden JL, Brugge R, Rabinowitz A, et al. The efficacy of long-term quetiapine treatment for the treatment of bipolar disorder.Am J Psychiatry.2008;180:e1251-e1262. [Accessed 26 Jan. 2010.Cite: BrBS..See also:
© Copyright 2010 The American Psychiatric Association.
Brugge R, Rabinowitz A. Quetiapine, a novel agent, for the treatment of bipolar disorder.2009;180:e1077-e1086. [Accessed 19 Apr.Cite: BrBS.[]
The quetiapine-induced increase in the incidence and severity of bipolar disorder.2008;180:e1077-e1086.
Cronieri S, Brugge R, Rabinowitz A. Efficacy of long-term quetiapine treatment for the treatment of bipolar disorder.Diagnol Res.2007;32:5-8. [Accessed 18 Mar.
Davies J, Brays H, Jorgensen B. Atypical antipsychotic drugs for the treatment of bipolar disorder.J Clin Psychiatry.2001;46:541-546. [Accessed 20 Feb.
Davies J, Brays H, Jorgensen B, et al.[Accessed 18 Feb.
Atypical antipsychotics for the treatment of bipolar disorder.
Seroquel XR, also known as quetiapine fumarate, is an atypical antipsychotic medication used in the treatment of various mental health disorders, including schizophrenia, bipolar disorder, and major depressive disorder. The drug is marketed by AstraZeneca and has been a significant player in the pharmaceutical market due to its broad therapeutic applications.
Seroquel XR, the main component of the drug, has been the subject of substantial research and has been shown to be a significant player in the pharmaceutical market, with a currently valued client consisting of Teva Pharmaceutical Industries to which we are also dedicated. As a member of this drug family, Seroquel has commercial roots in this medical profession and has been around since 2009. Teva was one of the first pharmaceutical companies to introduce the fluoroquinolone (clindamycin) antibiotic (chlordithiazine) in 1996.
The global Seroquel market was valued at approximately USD 44.66 billion in 2023 and is projected to reach USD 700.48 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 4.6% during the forecast period of 2024-2030. This is a significant growth rate due to the presence of AstraZeneca.
The Seroquel family includes Teva, AstraZeneca, Aurobindo Pharma, Splendid, Janssencia, Zydena, Teva Pharmaceuticals, and Teva Gyllenhaal.
The market is segmented based on several key factors:
The Asia-Pacific region is expected to dominate the Seroquel market, with a market size of USD 8.2 billion by 2030, with a CAGR of of 8.6% from 2024 to 2030. The region's approximately 12 million clientsthDAQ100+ patients is expected to grow by 2.1% during the forecast period.
The South is a regionally significant market with a significant market presence in Seroquel, with a market size of USD 128.66 million in 2023, with a CAGR of 5.7% from 2022 to 2023. The largest market in South isoquel, with a market size of USD 4.8 billion in 2023, with a CAGR of 10.1% from 2022 to 2023.
The market is segmented by the presence of:
The main drivers of Seroquel development in the Asia-Pacific region are:
Stade de France Pharmacy